ContraVir conducting Phase II studies for combination therapy in HBV

October 4, 2016 Christoph Graener

ContraVir CEO James Sapirstein talked with Informa Pharma Intelligence at BioPharm America 2016 about his company’s plans to improve on current therapies for hepatitis B (HBV) with lipid formulation of Viread, a standard-of-care drug in both HBV and HIV. Lead candidate CMX157 is in a pair of Phase II studies and ContraVir hopes that the drug will become a backbone agent for combination therapy in HBV, similar to the combination regimens that have revolutionized treatment for HIV and hepatitis C. Sapirstein also talked about ContraVir’s acquisition this past June of Ciclofilin Pharmaceuticals, which brought the company a preclinical drug candidate that could provide an immunomodulatory complement to CMX157.

Interviewer: Joe Haas – Senior Writer, The Pink Sheet, Informa
Interviewee: James Sapirstein – CEO, ContraVir Pharmaceuticals

Previous Article
Qualcomm Life brings players in the healthcare ecosystem toward digital transformation
Qualcomm Life brings players in the healthcare ecosystem toward digital transformation

Disruption to the healthcare ecosystem means disruption to a USD 4 trillion industry. This is no small feat...

Next Article
Novel approach to CAR T cell therapy at UPenn Center for Cellular Immunotherapies

Avery Posey outlines his work in CAR T therapy at the Center for Cellular Immunotherapies at UPenn during a...